The drug is approved in different countries as a treatment for colorectal, lung, breast and kidney cancer. • Non-squamous non-small cell lungcancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease. • Glioblastoma, as a single agent for adult patients with progressive disease following prior therapy. Lastly, we will explore the prognosis for glioblastoma patients undergoing Avastin therapy. By examining survivalrates, disease progression, and long-term outcomes, we gain a comprehensive perspective on theimpactofAvastinonpatients’ lives. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Approved for patients with advanced lung, colon or breast cancer, it cuts off tumors’ blood supply, an idea that has tantalized science for decades. And despite its price, which can reach $100,000 a year, Avastin has become one of the most popular cancer drugs in the world... Avastin gets prescribed for a variety of cancers, especially colon cancer, non-small cell lungcancer, metastatic breast cancer and glioblastoma multiforme — an incurable brain cancer. For the combination of Tecentriq, Avastin plus chemotherapy, tumor shrinkage rate was 64% compared with 48% in the Avastin plus chemotherapy arm. The Tecentriq study is the first phase III combination trial of a cancer immunotherapy to show improvement in progression-free...